Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M.

J Natl Cancer Inst Monogr. 2015 May;2015(51):1-3. doi: 10.1093/jncimonographs/lgv022.

PMID:
26063875
2.

Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review.

Gonzalez FM, Finch AP, Armeni P, Boscolo PR, Tarricone R.

Expert Rev Med Devices. 2015 Jul;12(4):471-85. doi: 10.1586/17434440.2015.1054807. Epub 2015 Jun 7.

PMID:
26051009
3.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.

PMID:
26044370
4.

Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.

Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F.

Eur Urol. 2014 Dec 4. pii: S0302-2838(14)01221-4. doi: 10.1016/j.eururo.2014.11.038. [Epub ahead of print] Review.

PMID:
25481455
5.

Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Beresniak A, Medina-Lara A, Auray JP, De Wever A, Praet JC, Tarricone R, Torbica A, Dupont D, Lamure M, Duru G.

Pharmacoeconomics. 2015 Jan;33(1):61-9. doi: 10.1007/s40273-014-0216-0.

PMID:
25230587
6.

Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?

Tarricone R, Torbica A, Ferré F, Drummond M.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):707-18. doi: 10.1586/14737167.2014.950233. Epub 2014 Sep 8. Review.

PMID:
25196848
7.

Genetic screening for the predisposition to venous thromboembolism: a cost-utility analysis of clinical practice in the Italian health care system.

Compagni A, Melegaro A, Tarricone R.

Value Health. 2013 Sep-Oct;16(6):909-21. doi: 10.1016/j.jval.2013.05.003. Epub 2013 Jul 16.

PMID:
24041341
8.

Explaining the health costs associated with managing intracranial aneurysms in Italy.

Calciolari S, Torbica A, Tarricone R.

Appl Health Econ Health Policy. 2013 Aug;11(4):427-35. doi: 10.1007/s40258-013-0041-1.

PMID:
23839310
9.

An economic perspective on urinary tract infection: the "costs of resignation".

Ciani O, Grassi D, Tarricone R.

Clin Drug Investig. 2013 Apr;33(4):255-61. doi: 10.1007/s40261-013-0069-x.

PMID:
23475540
10.

Assessing the added value of health technologies: reconciling different perspectives.

Drummond M, Tarricone R, Torbica A.

Value Health. 2013 Jan-Feb;16(1 Suppl):S7-13. doi: 10.1016/j.jval.2012.10.007. Epub 2012 Nov 14.

PMID:
23317646
11.

Setting the scene: the challenges of universal health coverage and the contribution of management education.

Tarricone R.

Value Health. 2013 Jan-Feb;16(1 Suppl):S4-6. doi: 10.1016/j.jval.2012.10.009. Epub 2012 Nov 14.

PMID:
23317644
12.

Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?

Ciani O, Tarricone R, Torbica A.

Health Policy. 2012 Dec;108(2-3):194-202. doi: 10.1016/j.healthpol.2012.09.017. Epub 2012 Oct 23.

PMID:
23093020
13.

Economic evidence of interventions for acute myocardial infarction: a review of the literature.

Callea G, Tarricone R, Lara AM.

EuroIntervention. 2012 Aug;8 Suppl P:P71-6. doi: 10.4244/EIJV8SPA12. Review.

PMID:
22917795
14.

Determinants of demand for total hip and knee arthroplasty: a systematic literature review.

Mota RE, Tarricone R, Ciani O, Bridges JF, Drummond M.

BMC Health Serv Res. 2012 Jul 30;12:225. doi: 10.1186/1472-6963-12-225. Review.

15.
16.

Applying health economics for policy decision making: do devices differ from drugs?

Sorenson C, Tarricone R, Siebert M, Drummond M.

Europace. 2011 May;13 Suppl 2:ii54-8. doi: 10.1093/europace/eur089.

17.
18.

Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review.

Bartoli S, Aguzzi G, Tarricone R.

Urology. 2010 Mar;75(3):491-500. doi: 10.1016/j.urology.2009.07.1325. Epub 2009 Dec 4. Review.

PMID:
19962738
19.

Economic evaluation for devices and drugs--same or different?

Drummond M, Griffin A, Tarricone R.

Value Health. 2009 Jun;12(4):402-4. doi: 10.1111/j.1524-4733.2008.00476_1.x. Epub 2008 Nov 19. No abstract available.

PMID:
19138306
20.

Cost-effectiveness analysis for trigeminal neuralgia: Cyberknife vs microvascular decompression.

Tarricone R, Aguzzi G, Musi F, Fariselli L, Casasco A.

Neuropsychiatr Dis Treat. 2008 Jun;4(3):647-52.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk